DRKS00004368Active, not recruitingPhase 4
Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple Sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Active, not recruiting
- Sponsor
- Philipps-Universität Marburg
- Enrollment
- 2
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 18 Years to 60 Years (—)
- Sex
- All
Inclusion Criteria
- •signed Informed Consent
- •- diagnosis of either relapsing remitting Multiple Sclerosis (RR-MS) or Clinically isolted syndrome (CIS)
- •- therapy naive
Exclusion Criteria
- •- diagnosis of primary or secondary progressive Multiple Sclerosis (PP-MS or SP-MS)
- •- diagnosis of any other autoimmune disorder
- •- actual or past treatment with Interferons, Glatirameracetate, Azathioprine, intravenous immunglobulin (IVIG), Natalizumab, Mitoxantrone, Cyclophosphamide, non-steroidal Antirheumatics or any other immunomodulating or immunosuppressive substances other than corticosteroids as relapse treatment
- •- positive pregnancy-testing in female patients
- •- inadequate contraception
- •- Hypersensitivity to Glatirameracetate or Mannitol
- •- othe contraindications against Copaxone
- •- participation in any other clinical trial
Investigators
Similar Trials
Active, not recruiting
Phase 1
Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUSPatients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive intestinal polypaptide/pituitary adenylate cyclase activating polypeptide) system in stresses patients who start a immunomodulatory treatment with glatiramer acetate (Copaxone).EUCTR2009-011088-35-DEPhilipps-Universität Marburg2
Completed
Not Applicable
PACAP27 Headache Properties in Migraine Without Aura PatientsMigraine Without AuraNCT03471039Danish Headache Center20
Completed
Not Applicable
The application of anti-cyclic citrullinated peptide autoantibody and soluble HLA-DR tests to the detection of early rheumatoid arthritis in New Zealand patients.Inflammatory and Immune System - Rheumatoid arthritisRheumatoid arthritisACTRN12606000277549isa Stamp80
Completed
Not Applicable
ltradian rhythms of cortisol after cardiac surgeryCoronary artery disease / surgery / endocrinologySurgeryMechanical complication of coronary artery bypass and valve graftsISRCTN22146594niversity of Bristol (UK)60
Recruiting
Not Applicable
The analysis of pituitary antigen in ACTH deficiency due to immune-related adverse events of PD1 antibodyJPRN-UMIN000040240Kochi University8